Piramal Pharma Share Price Surges Over 2%; US FDA Successfully Closes Sellersville Facility Inspection

Piramal Pharma Limited has announced the successful closure of a US Food and Drug Administration (US FDA) inspection at its manufacturing facility in Sellersville, Pennsylvania, USA. 

The company informed the stock exchanges that the US FDA has issued an Establishment Inspection Report (EIR), indicating that the regulatory inspection at the facility has been successfully concluded.  

US FDA Issues Establishment Inspection Report 

The company stated that the US FDA has issued an Establishment Inspection Report (EIR) for its Sellersville manufacturing facility. 

The issuance of the EIR signifies the successful completion and closure of the inspection conducted by the US regulator. Piramal Pharma had previously informed the exchanges about the inspection on May 10, 2026.  

Regulatory Milestone for Manufacturing Facility 

The successful closure of the inspection represents an important regulatory milestone for the Sellersville facility. 

Manufacturing facilities supplying pharmaceutical products to the US market are subject to periodic inspections by the US FDA to assess compliance with current Good Manufacturing Practices (cGMP) and applicable quality standards.  

Supports Global Manufacturing Operations 

Piramal Pharma operates a global network of manufacturing facilities serving customers across multiple regulated markets. 

The successful completion of the US FDA inspection supports the continued operations of the Sellersville facility and reinforces the company's focus on maintaining regulatory compliance and quality standards across its manufacturing network.  

Read More: Premier Energies Share Price in Focus as Company Inaugurates 5.6 GW Solar Module Plant in Telangana! 

Piramal Pharma Share Price Performance 

As of 09 July 2026, at 2:25 PM, Piramal Pharma share price was trading at ₹172.59 per share, reflecting a surge of 2.66% from the previous trading session. 

Conclusion 

Piramal Pharma has successfully concluded the US FDA inspection of its Sellersville, USA manufacturing facility after receiving an Establishment Inspection Report (EIR). The regulatory milestone reflects the successful closure of the inspection and supports the company's ongoing manufacturing operations in regulated markets.  

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.